الفهرس 
AcknowledgmentsOnly 14 pages are availabe for public view
 |  | from | 74 |  |  |
| | | from | 74 | | |
Abstract
Oral candidiasis (OC) is an opportunistic fungal infection, common amongst the elderly and
the immunocompromised. Unfortunately, the therapeutic efficacy of common antifungals is
imperiled by the rise of antifungal drug resistance. An alternative promising therapeutic option
possibly contributing to antifungal therapy is drug repurposing. Herein, we aimed to employ
novel pharmaceutical drug delivery for enhancing the emerging antifungal potential of the
hypocholesterolemic drug atorvastatin (ATV). ATV-propylene-glycol-liposomes (ATV/PGLip)
were prepared then integrated in 3D-printed (3DP) mucoadhesive films comprising
chitosan, polyvinyl-alcohol and hydroxypropyl methylcellulose, as an innovative blend, for the
management of OC. ATV/PG-Lip demonstrated good colloidal properties of particle size
(223.3 ± 2.1 nm), PDI (0.12 ± 0.001) and zeta potential (-18.2 ± 0.3 mV) with high entrapment
efficiency (81.15 ± 1.88%) and sustained drug release. Also, ATV/PG-Lip showed acceptable
three-month colloidal stability and in vitro cytocompatibility on human gingival fibroblasts.
The developed 3DP-films exhibited controlled ATV release (79.4 ± 1.4% over 24 h),